11th January 2024
Today, the University of Copenhagen shared the positive results of an investigational study, published in Blood providing ground-breaking evidence that Staphylococcus aureus and its toxins induce drug resistance in malignant T-cells against therapeutics such as HDAC inhibitors and chemotherapies commonly used for cutaneous T cell lymphoma (CTCL). Importantly, the study shows that bacterial killing by Micreos engineered, S. aureus-targeting endolysin countered this drug-resistance effect.
These new data further support the potential of endolysins as a novel therapeutic modality in CTCL. It is inspiring to follow Prof. Ødum and his amazing and visionary team at Copenhagen University and we are excited about the role Micreos’s solutions can play in advancing standards of care for CTCL patients.
Full press release including link to the full article: https://lnkd.in/